TABLE 1.
Tumor no. | Avg no. of transcripts
|
Presence of HRG | |
---|---|---|---|
HER4 | BRCA1 | ||
1 | 50 | 817 | − |
2 | 330 | 301 | + |
3 | 470 | 3,411 | − |
4 | 960 | 821 | − |
5 | 1,220 | 891 | + |
6 | 1,450 | 1,882 | − |
7 | 2,710 | 1,087 | + |
8 | 8,450 | 1,770 | + |
9 | 8,770 | 2,617 | − |
10 | 12,180 | 1,603 | − |
11 | 16,570 | 2,427 | + |
12 | 20,860 | 6,207 | + |
13 | 22,960 | 11,126 | + |
14 | 25,950 | 2,318 | − |
15 | 49,330 | 6,447 | − |
16 | 50,910 | 4,583 | + |
17 | 57,820 | 4,714 | + |
18 | 77,930 | 8,922 | + |
19 | 95,860 | 4,934 | + |
Breast cancer specimens were used to measure absolute levels of HER4 and BRCA1 mRNAs by qPCR. Each sample was independently analyzed three times. qPCR was used to detect the presence (+) or absence (−) of HRG in each of the breast tumor specimens.